Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CERo Therapeutics Holdings ( (CERO) ).
On August 28, 2025, CERo Therapeutics Holdings received a notification from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement of $2,500,000, risking suspension and delisting of its securities. The company has requested a hearing to present a plan to regain compliance, potentially through financing transactions, although there is no assurance of success.
The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions.
Average Trading Volume: 1,119,128
Technical Sentiment Signal: Sell
Current Market Cap: $8.92M
For an in-depth examination of CERO stock, go to TipRanks’ Overview page.